hrp0092p1-367 | GH and IGFs (2) | ESPE2019

Normal IGF-Bioactivity and Low Free IGF-I in Patients with Prader-Willi Syndrome with High Total Serum IGF-I: Immunoreactive IGF-I Concentration Poorly Reflects IGF Bio-Activity and Bio-Availability.

Elizabeth Melitza , Donze Stephany , Pellikaan Karlijn , van den Berg Sjoerd , van Doorn Jaap , Peeters Robin P. , Hokken-Koelega Anita C.S. , de Graaff Laura C.G.

Introduction: Recombinant Growth Hormone (GH) has changed the lives of many patients with Prader-Willi Syndrome (PWS). GH treatment has beneficial effects on body composition, physical performance, cognition, psychomotor development, respiratory function and quality of life of patients with PWS. Due to the narrow therapeutic range, GH treatment is subject to strict limits. Clinicians measure serum immunoreactive Insulin-like Growth Factor 1 ('total IGF-I&#...

hrp0086p2-p700 | Endocrinology and Multisystemic Diseases P2 | ESPE2016

Effects of 2 Years of Growth Hormone Treatment on Glucose Tolerance in Young Adults with Prader-Willi Syndrome

Donze Stephany , Kuppens Renske , Bakker Nienke , Hokken-Koelega Anita

Background: Growth hormone treatment (GH) in children with PWS results in an improvement in height velocity, body composition and mental and motor development. Discontinuation of GH after attainment of adult height (AH) leads to a decrease in lean body mass and an increase in body fat percentage, which results in an increased risk of impaired glucose tolerance (IGT) and diabetes mellitus type 2 (DM2). Studies in adults with PWS suggest positive effects of GH, but GH is known t...

hrp0082p1-d1-173 | Perinatal and Neonatal Endocrinology | ESPE2014

A Girl with Beckwith–Wiedemann Syndrome and Pseudohypoparathyroidism Type 1B, a Unique Example of Multiple Imprinting Defects

Bakker Boudewijn , Sonneveld Laura , Woltering Claire , Kant Sarina

Background: Although multiple imprinting defects have been found by genetic analysis in a subset of patients with Beckwith–Wiedemann Syndrome (BWS), very few patients have been described with both genetic and clinical signs and symptoms of multiple diseases caused by imprinting defects.Methods: Methylation analysis of the KCNQ1OT1 gene was performed by Southern blot, methylation analysis of the GNAS region was done by MLPA.<p class="abs...

hrp0082p1-d1-200 | Reproduction | ESPE2014

Testes in Infants with Prader–Willi Syndrome: hCG Treatment, Surgery, and Histology

Bakker Nienke , Wolffenbuttel Katja , Looijenga Leendert , Hokken-Koelega Anita

Background: Boys with PWS often have unilateral or bilateral cryptorchidism. Prospective studies on the treatment of cryptorchidism in boys with PWS are lacking and there is no treatment consensus among pediatricians and urologists.Objective and hypotheses: We hypothesized that hCG treatment would lead to a scrotal position of the testes in infants with PWS and cryptorchidism. We therefore evaluated the effects of hCG treatment on testis position. Additi...

hrp0092rfc13.3 | Adrenals and HP Axis | ESPE2019

Establishment of Reference Intervals for Hair Cortisol in Healthy Children Aged 0-18 Years Using Mass Spectrometric Analysis

de Kruijff Ineke , Noppe Gerard , Kieviet Noera , Choenni Vandhana , Lambregtse-van den Berg Mijke , Begijn Dominique , Tromp Ellen , Dorst Kristien , van Rossum Elisabeth , de Rijke Yolanda , van den Akker Erica

Background: Human scalp hair is a valuable matrix for determining long-term cortisol concentrations, with wide-spread applicability in clinical care as well as research. However, pediatric reference intervals are lacking.The aim of this study is to establish age-adjusted reference intervals for hair cortisol in children aged 0-18 years and to gain insight into hair-growth velocity in children up to 2 years old.Methods: A...

hrp0094p1-5 | Adrenal A | ESPE2021

Alterations in resting-state functional connectivity in patients with congenital adrenal hyperplasia

Messina Valeria , van´t Westeinde Annelies , Padilla Nelly , Lajic Svetlana ,

Background: Patients with congenital adrenal hyperplasia (CAH) are treated with life-long glucocorticoid (GC) replacement therapy. Negative effects on cognition, brain structure and function during working memory tasks have been identified. To date, no studies on functional connectivity during rest have been performed in patients with CAH. One study conducted on patients with Cushing’s syndrome, another disorder of cortisol imbalance, suggests that long-t...

hrp0097p2-309 | Late Breaking | ESPE2023

The making of the EndoWatch: A new device for Early Monitoring of Hypothalamic imbalances.

Hulsmann Sanne , Petras Sarah , Fraboulet Philippe , Lu Yuan , van Santen Hanneke

Title: The making of the EndoWatch: A new device for Early Monitoring of Hypothalamic imbalances. Hulsmann S, Petras S, Fraboulet P, Yuan Lu, van Santen HM (on behalf of the EndoWatch team) Keywords: Paediatric and adolescent cancer survivors, Brain tumour, Quality of Life, Wearable, Hypothalamic Obesity Main goals: Aim for better quality of lifeIntroduction: Children and adults with a suprasellar (hypothalamic)...

hrp0089rfc4.6 | GH &amp; IGFs | ESPE2018

Effect of 2 Years of Growth Hormone Treatment on Glucose Tolerance in Adults with Prader-Willi Syndrome

Damen Layla , Donze Stephany , Kuppens Renske , Bakker Nienke , Hokken-Koelega Anita

Background: In children with Prader-Willi syndrome (PWS), the benefits of growth hormone (GH) treatment are well established. GH has substantially changed the phenotype of children with PWS. Discontinuation of GH after adult height (AH) attainment leads to a decrease in lean body mass and an increase in body fat percentage. Due to their abnormal body composition, adults with PWS are predisposed to develop impaired glucose tolerance (IGT) and diabetes mellitus type 2 (T2DM). Re...

hrp0095p2-153 | GH and IGFs | ESPE2022

Avascular necrosis of the hip as a rare complication of growth hormone therapy

van der Linde Annelieke , van Baelen Amber , van Bergen Christiaan

Background: Growth hormone therapy can be indicated for children who are born small for gestation age (SGA) (either birth weight or birth height < -2 SDS) without catch-up growth (height < -2.5 SDS) at age 4 years. Growth hormone therapy is considered a safe treatment.Case presentation: A 12-year-old girl was referred to the pediatric endocrinologist for short stature. She was born small for gestational age (birth ...

hrp0084p2-384 | Fat | ESPE2015

Obesity in ROHHADNET Syndrome: Does Cortisol Play a Role?

van Tellingen Vera , van Trotsenburg Paul

Background: ROHHADNET syndrome is characterised by rapid onset childhood obesity, hypoventilation, variable hypothalamic-pituitary and autonomic dysfunction, and neuroendocrine tumors in 30–40%. Autoimmunity and paraneoplastic syndrome have been proposed as possible pathophysiological mechanisms, but the exact aetiology remains unclear.Objective and hypotheses: We present the clinical course of ROHHADNET syndrome in a 17-year-old girl, with consecut...